Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?
Chronic liver diseases (CLDs) are a public health problem, even if frequently they are underdiagnosed. Hepatic steatosis (HS), encountered not only in nonalcoholic fatty liver disease (NAFLD) but also in chronic viral hepatitis, alcoholic liver disease, etc., plays an important role in fibrosis prog...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2021/6662760 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564813216088064 |
|---|---|
| author | Roxana Sirli Ioan Sporea |
| author_facet | Roxana Sirli Ioan Sporea |
| author_sort | Roxana Sirli |
| collection | DOAJ |
| description | Chronic liver diseases (CLDs) are a public health problem, even if frequently they are underdiagnosed. Hepatic steatosis (HS), encountered not only in nonalcoholic fatty liver disease (NAFLD) but also in chronic viral hepatitis, alcoholic liver disease, etc., plays an important role in fibrosis progression, regardless of CLD etiology; thus, detection and quantification of HS are imperative. Controlled attenuation parameter (CAP) feature, implemented in the FibroScan® device, measures the attenuation of the US beam as it passes through the liver. It is a noninvasive technique, feasible and well accepted by patients, with lower costs than other diagnostic techniques, with acceptable accuracy for HS quantification. Multiple studies have been published regarding CAP performance to quantify steatosis, but due to the heterogeneity of CLD etiologies, of steatosis prevalence, etc., it had widely variable calculated cut-off values, which in turn limited the day-to-day utility of CAP measurements in clinical practice. This paper reviews published studies trying to suggest cut-off values usable in clinical practice. |
| format | Article |
| id | doaj-art-3039f1fc6a95440b805ef3a6064c6c5d |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-3039f1fc6a95440b805ef3a6064c6c5d2025-02-03T01:10:08ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972021-01-01202110.1155/2021/66627606662760Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?Roxana Sirli0Ioan Sporea1Department of Gastroenterology and Hepatology, Advanced Regional Research Center in Gastroenterology and Hepatology, “Victor Babeş” University of Medicine and Pharmacy, 156, Liviu Rebreanu Bv., Timişoara 300723, RomaniaDepartment of Gastroenterology and Hepatology, Advanced Regional Research Center in Gastroenterology and Hepatology, “Victor Babeş” University of Medicine and Pharmacy, 156, Liviu Rebreanu Bv., Timişoara 300723, RomaniaChronic liver diseases (CLDs) are a public health problem, even if frequently they are underdiagnosed. Hepatic steatosis (HS), encountered not only in nonalcoholic fatty liver disease (NAFLD) but also in chronic viral hepatitis, alcoholic liver disease, etc., plays an important role in fibrosis progression, regardless of CLD etiology; thus, detection and quantification of HS are imperative. Controlled attenuation parameter (CAP) feature, implemented in the FibroScan® device, measures the attenuation of the US beam as it passes through the liver. It is a noninvasive technique, feasible and well accepted by patients, with lower costs than other diagnostic techniques, with acceptable accuracy for HS quantification. Multiple studies have been published regarding CAP performance to quantify steatosis, but due to the heterogeneity of CLD etiologies, of steatosis prevalence, etc., it had widely variable calculated cut-off values, which in turn limited the day-to-day utility of CAP measurements in clinical practice. This paper reviews published studies trying to suggest cut-off values usable in clinical practice.http://dx.doi.org/10.1155/2021/6662760 |
| spellingShingle | Roxana Sirli Ioan Sporea Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? Canadian Journal of Gastroenterology and Hepatology |
| title | Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? |
| title_full | Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? |
| title_fullStr | Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? |
| title_full_unstemmed | Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? |
| title_short | Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? |
| title_sort | controlled attenuation parameter for quantification of steatosis which cut offs to use |
| url | http://dx.doi.org/10.1155/2021/6662760 |
| work_keys_str_mv | AT roxanasirli controlledattenuationparameterforquantificationofsteatosiswhichcutoffstouse AT ioansporea controlledattenuationparameterforquantificationofsteatosiswhichcutoffstouse |